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Abstract
The increasing chronicity and multimorbidities associated with people living with HIV have posed important challenges 
to health systems across the world. In this context, payment models hold the potential to improve care across a spectrum 
of clinical conditions. This study aims to systematically review the evidence of HIV performance-based payments models. 
Literature searches were conducted in March 2020 using multiple databases and manual searches of relevant papers. Papers 
were limited to any study design that considers the real-world utilisation of performance-based payment models applied to 
the HIV domain. A total of 23 full-text papers were included. Due to the heterogeneity of study designs, the multiple types 
of interventions and its implementation across distinct areas of HIV care, direct comparisons between studies were deemed 
unsuitable. Most evidence focused on healthcare users (83%), seeking to directly affect patients’ behaviour based on prin-
ciples of behavioural economics. Despite the variability between interventions, the implementation of performance-based 
payment models led to either a neutral or positive impact throughout the HIV care continuum. Moreover, this improvement 
was likely to be cost-effective or, at least, did not compromise the healthcare system’s financial sustainability. However, more 
research is needed to assess the durability of incentives and its appropriate relative magnitude.
Keywords Acquired Immunodeficiency Syndrome · HIV infections · Multimorbidity · Healthcare Financing · Payment 
Models · Economic
Resumen
La creciente cronicidad y multimorbilidades asociadas con las personas que viven con el VIH han planteado importantes 
desafíos para los sistemas de salud en todo el mundo. En este contexto, los modelos de pago tienen el potencial de mejorar 
la atención en un espectro de condiciones clínicas. Este estudio tiene como objetivo revisar sistemáticamente la evidencia de 
los modelos de pagos basados  en el desempeño aplicados al dominio del VIH. Las búsquedas bibliográficas se realizaron en 
marzo de 2020 utilizando múltiples bases de datos y búsquedas manuales de artículos relevantes. Los artículos se limitaron 
a cualquier diseño de estudio que considere la utilización en el mundo real de modelos de pago basados  en el desempeño 
aplicados al dominio del VIH. Se incluyeron un total de 23 artículos de texto completo. Debido a la heterogeneidad de los 
diseños de los estudios, los múltiples tipos de intervenciones y su implementación en distintas áreas de la atención del VIH, 
las comparaciones directas entre diferentes estudios se consideraron inadecuadas. La mayoría de la evidencia se centró en los 
usuarios de la salud (83%), buscando afectar directamente el comportamiento de los pacientes basándose en los principios 
de la economía del comportamiento. A pesar de la variabilidad entre las intervenciones, la implementación de modelos de 
pago basados  en el desempeño generó un impacto neutral o positivo en todo el proceso de atención del VIH. Además, es 
probable que esta mejora sea costo-efectiva o, al menos, no comprometa la sostenibilidad financiera del sistema de salud. 
Sin embargo, se necesita más investigación para evaluar la durabilidad de los incentivos y su magnitud relativa apropiada.
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Introduction
The HIV / AIDS epidemiological evolution remains chal-
lenging across the world. Whilst low to intermediate-income 
countries have focused on tackling new infections and the 
spread of the disease, the epidemiological evolution in high-
income countries has led to people with HIV living longer, 
and with multiple comorbidities [1]. This increase in chro-
nicity and multimorbidities associated with people living 
with HIV is posing important challenges to health systems 
across the world [2]. In fact, given the increasing medical 
costs per person living with HIV infection [3] and the ever-
growing budget constraints, transformational changes in 
both the HIV care delivery and payment models are required 
[4].
Multiple payment models have been tested in healthcare, 
typically characterised based on its: (i) recipients; and (ii) 
payment unit(s). First, concerning the model’s recipients, 
payment models are typically utilised to reimburse health-
care providers for their services. However, payment models 
are also used to cascade down institutional incentives to 
the individual level, either to incentivise healthcare profes-
sionals or the healthcare users themselves. Second, regard-
ing the unit payment, historical unit payments centered on 
retrospective cost reimbursements have been progressively 
replaced with prospective unit payments, particularly based 
on activity (e.g. fee-for-service, bundled payments per epi-
sode or per diagnosis) or capita. More recently, payment 
models have moved from volume to value-based unit pay-
ments, with the implementation of performance-based 
payment models which aim to improve quality of care and 
decrease overall costs [5]. Different unit payments present 
diverse advantages and disadvantages, leading to the coexist-
ence of multiple unit payments across different production 
lines (e.g. ambulatory care, admissions), care providers or 
even healthcare systems [2, 3]. As an example, if the model’s 
aim is to improve healthcare access, then volume-based unit 
payments may be appropriate, whilst if the aim is to enhance 
disease prevention, the capita unit payment system may be 
more appropriate. In essence, the payment model’s structure 
should be aligned with its overall aim.
Given the high mean healthcare cost per person living 
with HIV infection [3], payment models must balance: (i) 
the financial risk for all stakeholders; (ii) the promotion of 
quality of care and care integration [1, 2]; and (iii) multiple 
recipients, from healthcare providers, healthcare profes-
sionals or even the people living with HIV themselves [6]. 
For these reasons, novel HIV payment models tend to be 
performance-based as opposed to volume-based.
Over the past decade, multiple reviews evaluated the 
impact of performance-based HIV payment models [7–15], 
which can be grouped according to: the healthcare set-
ting considered (low to intermediate-income countries vs 
high-income countries); and the area of HIV care consid-
ered (from HIV testing and HIV prevention to adherence to 
treatment). Notably, a systematic literature review published 
in 2017 assessed the implementation of performance-based 
payment models in low-income countries [13]. Only four 
studies were included in this review and the authors con-
cluded there was little evidence regarding the real-world 
implementation of HIV payment models.
The present manuscript builds upon previous reviews but 
presents four innovative features. First, contrary to previ-
ous studies that only consider high or low-income countries, 
this review did not exclude evidence based on the study’s 
country of origin. Second, this review aimed to capture any 
performance-based payment model regardless of its recipi-
ent (healthcare providers, health professionals or healthcare 
users). Third, the entire HIV continuum of care was consid-
ered, from prevention to the treatment of people living with 
HIV. Previous evidence tended to focus on a specific area, 
either HIV prevention, adherence to treatment or the deliv-
ery of antiretroviral treatment (ART). Fourth, linked to the 
increasing chronicity of HIV in high-income countries, the 
review included search terms concerning the use of payment 
models in the context of multimorbidity.
As a corollary, this systematic literature review aims to 
summarise the real-world evidence around the implementa-
tion of HIV performance-based payment models and provide 
a solid foundation on which to base decisions from health-
care policy makers across multiple healthcare settings.
Methods
A systematic literature review was conducted to analyse any 
empirical evidence around the implementation of payment 
models in the field of HIV / AIDS. This systematic review 
was conducted in accordance with the Preferred Items for 
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment using a pre-defined protocol (International Prospective 
Register of Systematic Reviews, PROSPERO identification 
number CRD42020167941) [16].
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Search Strategy and Databases
The search strategy was defined based on the PICOS (Popu-
lation, Intervention, Comparator, Outcome, Study design) 
framework, as summarised in Table 1. The following elec-
tronic databases were searched: MEDLINE (PubMed), 
SCOPUS, Emerald, Web of Science, and the Cochrane 
Library. The search strategy (Online Appendix 1) was con-
sistently used in the databases searched, with only minor 
adjustments specific to the database searched. The use of 
truncation, wildcards, and Boolean logic aimed at maximis-
ing the number of relevant articles. In addition, references 
cited in the identified papers were also examined. In sum-
mary, the search strategy aimed to include studies of any 
design which evaluated the clinical and/or financial impact 
of implementing real-world payment models across the HIV 
continuum of care.
Inclusion and Exclusion Criteria
The inclusion and exclusion criteria were defined as per the 
PICOS strategy (Table 1). As inclusion criteria we consid-
ered: (i) studies including adults living with HIV/AIDS aged 
18 years or older (studies including children were included 
if the data had been disaggregated by age group for adults 
aged ≥ 18 years); (ii) studies, regardless of its design, in 
which clinical and/or economic outcomes related to the 
implementation of performance-based payment models were 
considered; (iii) studies published from 01/01/2008 onwards; 
and (iv) studies published in English. The age group was 
limited to adults as performance-based payment models are 
typically aimed at adults who live with the HIV infection or 
are at-risk of contracting the infection. With regards to the 
time frame, the utilisation of behavioural economics applied 
to the HIV domain has been quite recent, particularly after 
the introduction of HIV antiretroviral drugs. As an exclusion 
criterion, non-human studies were excluded.
Screening and Data Extraction
Figure 1 illustrates the process of study selection and data 
extraction. Abstracts were independently screened by two 
reviewers (TR, DB) and included or excluded as per the 
screening protocol. Full texts of selected articles were 
retrieved and independently assessed by two reviewers 
(TR, DB) for consistency in alignment with the review’s 
inclusion and exclusion criteria. Both investigators indi-
cated the reason(s) to include or not include each study in 
the systematic review. Any disagreements in the screening 
of abstracts and data extraction from full text papers were 
reached through consensus and, if not possible, by a third 
reviewer (VN). The data extraction methodology consid-
ered the collation of the following data in an electronic form 
spreadsheet (using Microsoft Excel):
Study description: record number, authors, study title, 
year, journal, country, study period, source of funding 
(e.g. public, private, social sector), reference, study meth-
ods;
Study and participant details: study objectives, study 
design, study inclusion and exclusion criteria, recruitment 
procedures used, participants’ allocation methods, popu-
lation description (e.g. age, sex, socio-economic status of 
participants, sample size, CD4 count, ART status);
Intervention and reported outcomes: intervention and 
comparator, primary and secondary outcomes measures, 
period of follow up, subgroup analysis, subgroup details 
(if applicable), sensitivity analysis;
Key findings, summary of study strengths and limitations.
All bibliographic references were managed (e.g. elimi-
nation of duplicates) using the bibliography management 
software Zotero.
Quality Assessment
Two reviewers (TR, DB) assessed the risk of bias of each 
included study using the ‘Mixed Method Appraisal Tool 
(MMAT)’ [17]. MMAT contains 19 core criteria in a quality 
scoring system which are grouped into five methodological 
categories, according to the study design: qualitative, quan-
titative with randomisation, quantitative without randomisa-
tion, quantitative descriptive studies and mixed methods.
Table 1  PICOS strategy considered in the systematic literature review
Population Adults (over 18 years old) with HIV/AIDS or adults considered eligible for HIV prevention or screening programmes
Intervention Any type of performance-based payment model
Comparator No additional payment model (e.g. existing standard of care)
Outcomes Clinical outcomes, both process (e.g. proportion of HIV patients in antiretroviral therapy) and result outcomes (e.g. proportion of 
HIV patients with supressed viral load)
Financial outcomes (e.g. mean cost per treated patient, mean cost per provider or patient included in the payment model)
Study design Any study regardless of the methodology used (e.g. qualitative study, quantitative study, mixed methods study) published from 
2008 onwards
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Results
A total of 23 full text studies were included in the review 
(see Fig. 1). These presented different methodologies in 
terms of: study design; country of origin; recipient of the 
intervention; type of intervention; clinical evidence; and 
economic evidence. For these reasons it was not deemed 
appropriate to summarise the evidence using meta-anal-
yses and instead a descriptive synthesis of evidence was 
undertaken. Table 2 summarises the key methodologi-
cal information extracted from the 23 studies included. 
Table 3 illustrates the clinical and economic results from 
the 23 studies included in this systematic review (for 
detailed information please refer to Online Appendix II). 
The evidence in the appendices are listed in chronological 
order (newest to oldest) and grouped per study design.
Study Design
Of the 23 articles included, 15 (65%) articles reported ran-
domised clinical trials [19–33], 4 (17%) non-randomised 
empirical studies [34–37] and 4 (17%) quantitative descrip-
tive studies with cost-effectiveness analyses [38–41].
Country of Origin
The studies included were classified according to their 
country of origin (see Table 2), given that interventions 
with payment models have the potential to be diversi-
fied according to the country in which the intervention 
is implemented. Thirteen out of 23 (57%) papers were 
derived from countries with high-income levels, specifi-
cally the USA (11 studies), the UK and Australia (1 study 
each). The remaining 10 (43%) articles were derived from 
Fig. 1  PRISMA flow chart sum-
marising the selection process 
of relevant studies
Records identified through database 
searching (n=7,339): 
Ovid PubMed (n=3,103); Cochrane 
(n=1,474); Emerald (n=556); Scopus 
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OECD (n=2); UNAIDS (n=2); World 
Bank (n=1)






No results of interest (n=3,293)
No information in abstract field (n=1,400)
Quantitative studies without payment 
model (n=945)
Duplicates (n=212)
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Not a language of interest (n=70)
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for eligibility (n = 66)
Full-text articles excluded, with 
reasons
(n = 33)
No outcome or result of interest (n=17)
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Studies included 
(n = 33)
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Table 3  Impact of the different payment models across five areas of HIV care
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several African countries with low to medium-income lev-
els: Uganda (3 studies), Tanzania (2 studies) and Malawi, 
South Africa, Mozambique, Swaziland and Rwanda (1 
study each).
Intervention’s Recipient
The payment model may also vary depending on its recipi-
ents: (i) health organisations; (ii) health professionals; and 
(iii) health care users themselves. A total of 19 of 23 articles 
(83%) focused on health users, followed by 7 of 23 (30%) 
articles with an emphasis on health organisations and no evi-
dence on healthcare professionals. Three articles simultane-
ously incentivised health organisations and health care users.
Type of Intervention
Different studies have considered various interventions, 
particularly regarding the model’s unit payment. However, 
the evidence presented a common denominator as all inter-
ventions that aimed to change the behaviour of health users 
deployed positive financial incentives.
All seven papers that focused on health organisations con-
sidered the use of incentives based on pay-for-performance. 
However, the rationale inherent as to how incentives aimed 
to change organisational behaviours varied, as did the area 
of  HIV on which the incentives were focused. At the health 
care users’ level, the empirical evidence (19 articles) con-
centrated mostly on the use of financial incentives to change 
behaviours across the various areas of HIV. These financial 
incentives were always positive incentives, with a view of 
promoting appropriate behaviour, and not negative incen-
tives aimed at inhibiting incorrect behaviours. However, 
these incentives varied greatly in terms of structure, with 
financial incentives being attributed as: (i) a fixed compo-
nent, where incentives were paid to all participants regard-
less of the results obtained; (ii) based on a lottery, where 
only one or more participants received incentives based on 
a random draw; and / or (iii) a conditional component, where 
there is only room for payment (partial or total) depending 
on the achievement of certain objectives, usually around 
clinical indicators associated with HIV management. It 
should be noted that most studies in low-income countries 
considered the use of fixed incentives whilst in high-income 
countries these tended to be conditional. Moreover, different 
incentive structures were not mutually exclusive, as some 
payment models were hybrid, with fixed incentives comple-
mented by conditional ones. In addition, in countries with 
low to intermediate income levels, some models included 
the use of non-financial incentives, such as the allocation of 
food items or food vouchers.
Clinical Evidence
The clinical evidence presented in the systematic review 
was grouped along the continuum of HIV care accord-
ing to five areas: (i) HIV prevention; (ii) HIV testing and 
screening; (iii) link to HIV care and initiation of antiret-
roviral therapy; (iv) retention in health care and adherence 
to treatment; and (v) viral suppression. Table 3 illustrates 
the empirical clinical evidence taken from the 23 studies, 
with the detailed view presented in Online Appendix II. 
Prospective studies, such as randomised clinical trials and 
observational studies, tended to be restricted to only one 
or two areas of HIV and not to the complete continuum of 
care. Irrespective of the study considered, the implementa-
tion of payment models led either to a neutral or positive 
impact across the five areas of HIV considered (Table 3). 
As an example, a recent randomised clinical trial by El-
Sadr et al. (2019) [19] assessed the impact of individual 
financial incentives in two areas of HIV care: continuity of 
healthcare (proportion of patients with CD4 + count in 4 
of the last 5 quarters); and viral suppression (proportion of 
patients with a viral load below 400 copies per ml among 
patients with at least 2 counts in the last 5 quarters). A 
higher proportion of participants in the intervention group 
showed greater continuity of health care compared to 
the control group (7.5%, p = 0.007, t-test) and exhibited 
a trend towards improved HIV viral suppression (2.7%, 
p = 0.076, t-test).
Economic Evidence
Regarding the magnitude of incentives, empirical evidence 
suggests that, regardless of the model’s recipient, the prob-
ability of influencing behaviours increases with the respec-
tive magnitude of the incentive (see Online Appendix II). 
In other words, the greater the incentive, the more likely to 
influence behaviours. Moreover, in the context of behav-
ioural economics, more than the absolute value of the incen-
tive, it is important to relate the magnitude of the incentive 
to the level of income of each participant (relative value of 
the incentive compared to the level of income of the par-
ticipant). For example, studies carried out on the African 
continent presented lower incentives [between $ 1 and $ 40 
when compared to high-income countries, such as the USA 
(average cost between $ 100 and $ 1173)], but their relative 
value compared to the respective average income per par-
ticipant tends to be comparable or even higher.
Only one study analysed the durability of the results 
following the implementation of the payment model [19]. 
In this study, a randomised clinical trial [19], the findings 
from the payment model were sustained 9 months post its 
implementation.
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Critical Appraisal
The risk of bias associated with each study was assessed 
using the MMAT. Fifty-two percent (12/23) of papers 
included presented ‘high quality’, 43% (10/23) ‘intermedi-
ate quality’ and 4.3% (1/23) ‘low quality’ (Table 2). Ran-
domised controlled trials and modelling studies (cost-effec-
tiveness studies) scored higher compared to non-randomised 
trials.
Discussion
Despite the design of the search terms, aimed at maximis-
ing the empirical evidence to include, the systematic litera-
ture review demonstrated the existence of limited empirical 
evidence around the implementation of payment models in 
the field of HIV and / or multimorbidities. The 23 articles 
included in the review showed important differences, con-
cerning: (i) the country of origin; (ii) the type of study; (iii) 
recipient of the model; (iv) HIV care area considered; and 
(v) the type of intervention considered.
First, 57% (13/23) of the papers came from high-income 
countries, particularly the USA (11/13). The remaining 43% 
(10/23) studies come from seven countries on the African 
continent. The main difference between studies from low 
and high-income countries resided in the area of  HIV care 
that the model seeks to impact, and not the type of study 
or the intervention’s recipient. Studies from low-income 
countries tended to focus on HIV prevention, HIV testing 
and screening, linkage to HIV care and initiation of antiret-
roviral therapy, whilst high-income countries tended to 
target subsequent dimensions of the continuum of care, in 
particular health care retention, adherence to treatment and 
viral suppression. This evidence seems to be consistent with 
the key issues that the interventions tried to address. The 
high incidence and vertical transmission of HIV in African 
countries is the key issues that health systems currently face, 
whereas in high-income countries, health systems have more 
difficulties around the integration of care, retaining people 
with HIV in antiretroviral therapy and ultimately suppress 
viral load.
Second, there were no differences concerning the impact 
of different payment models depending on the type of study, 
with all studies showing either a neutral or positive impact.
Third, the interventions centred on two distinct levels of 
recipients, health organisations and health care users them-
selves. No study aimed to incentivise health professionals. 
Most evidence focused on health care users (83%), followed 
by health organisations (30%). The fact that most interven-
tions targeted health users themselves, i.e. people at higher 
risk of HIV infection and/or people living with HIV infec-
tion, is aligned with behavioural economics theories [41] 
and reflects the individual importance of the user in the 
context of the entire care continuum. The inherent rationale 
is that health systems should devote financial resources to 
change the way users behave, seeking to enhance the cost-
effectiveness of the care provided. Although this approach is 
consistent and independent of the health system considered, 
there is an important difference depending on the income 
level of the country of origin. Low-income countries aimed 
to promote cost-effectiveness by focusing on reducing infec-
tion rates and the initiation of antiretroviral therapy whilst 
high-income countries focused on promoting adherence to 
antiretroviral therapy and, ultimately, achieve viral suppres-
sion. The inherent rationale is to improve quality of life of 
people living with HIV, while avoiding costly episodes of 
hospitalisation in patients without viral suppression.
Fourth, five areas along the HIV care continuum were 
considered. As illustrated in Table  2, different papers 
focused on one or several areas, with 43% (10/23) of articles 
assessing the impact on viral suppression, followed by 30% 
(10/23) around HIV prevention and retention in healthcare 
and adherence to treatment and 22% (5/23) in the remaining 
areas (HIV testing and screening; link to HIV care and early 
antiretroviral therapy). It should be noted that the evidence 
surrounding viral suppression derived mainly from high-
income countries.
Fifth, about the intervention, i.e. the payment model, this 
usually includes the use of financial incentives to encour-
age both health organisations and their users. These pay-
ments were mostly fixed, followed by conditional payments 
or based on lotteries. The use of conditional incentives is 
particularly relevant in: (i) care retention, where the user or 
organisation is only reimbursed according to consecutive 
indicators of access to care (e.g. consecutive CD4 counts); 
and (ii) viral suppression, where the user or organisation 
is only incentivised if viral suppression is achieved and/or 
sustained (e.g. CD4 counts below a given clinical objective). 
Contrary to some theory of behavioural economics, these 
incentives were always of a positive nature, that is, aimed at 
promoting behaviours, and not negative ones, which aim to 
inhibit behaviours (“carrot and not the stick”). A final point 
was the use of non-financial incentives (e.g. food items, 
smart phones) in studies developed in low-income countries.
Despite these methodological differences, the implemen-
tation of payment models presented a neutral or positive 
impact throughout the HIV care continuum. In fact, no study 
has shown a negative impact from applying the intervention 
with a payment model. This means that payment models 
improved the care provided under different dimensions of 
analysis, particularly in terms of access and quality of care. 
In particular, one high-quality randomised clinical trial con-
ducted in the USA (HPTN 065 study) showed that the use 
of payment models led to a statistically significant improve-
ment in the suppression of HIV viral loads [27]. These 
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findings, consistent throughout the evidence analysed, seem 
to reflect the potential for pay-for-performance to improve 
HIV care. However, publication biases were not formally 
assessed.
Additionally, the financial impact of the intervention 
appears to be aligned with the financial sustainability of 
the health system itself. When considering the four studies 
that evaluated the cost-effectiveness of HIV payment mod-
els [38–41], these were found to have a high probability of 
being cost-effective taking into account the usual financial 
envelopes of the health systems (“willingness-to-pay thresh-
olds”). This means that the interventions represent “value for 
money” and the increased costs associated with the payment 
model were more than offset by the avoided costs and / or 
by improving the quality of life of people living with HIV 
infection.
In terms of economic findings, the magnitude of the pay-
ment seems to be associated with the probability of success 
of the respective intervention. In the context of behavioural 
economics, more than the specific value of the incentive 
(absolute value), it is important to relate the magnitude of 
the incentive to the level of income of each participant (rela-
tive value of the incentive compared to the level of income 
of the participant). Finally, there was little evidence regard-
ing the durability of the impact of the intervention. More 
research is needed to understand the long-term implications 
and sustainability of payment models in changing organisa-
tional and patients’ behaviours.
Lastly, payment models in the HIV domain are at an 
early stage of development. This situation is similar to the 
payment models used in the context of patients with mul-
timorbidity [42]. However, due to the increasing chronicity 
associated with HIV, novel payment models should consider 
HIV in the context of other clinical conditions (e.g. diabe-
tes, mental health). Also, general payment models hold the 
potential to indirectly affect HIV care. For instance, a pay-
ment model that incentivises healthy habits or diabetes care 
holds the potential to impact patients who also live with an 
HIV infection. For these reasons, further research on the 
real-world implementation and cost-effectiveness of new or 
novel payment models is strongly recommended.
Review Limitations
The present review covers a period of 12 years (since 2008). 
The authors believe the exclusion of studies prior to 2008 
constitutes a minor limitation as most relevant performance-
based payment models, particularly in high-income coun-
tries, were constituted following the introduction of HIV 
antiretroviral drugs. The review includes only HIV specific 
performance-based payment models. Therefore, the potential 
impact of generic payment models across HIV patients is not 
included, which constitutes a review limitation. Given its 
broad inclusion criteria, all range and heterogeneity of stud-
ies conducted in different health care settings were included 
in the review. Despite this, a small number of studies (23) 
were included. The quality of these studies was assessed 
using the MMAT methodology, but no individual assessment 
of publication biases was conducted. Although a limitation, 
the authors believe that the review’s findings are likely to 
reflect the real-world implementation of HIV-based perfor-
mance payment models. Lastly, given the non-comparability 
of the studies retrieved, we conducted a narrative review and 
not a meta-analysis.
Conclusion
This review summarised the evidence around the use of 
performance-based payment models in the context of HIV 
and multimorbidity. Despite the very limited amount of evi-
dence and its heterogeneity, the utilisation of payment mod-
els seemed to be associated with neutral or positive impact 
across different dimensions of HIV care and was likely to be 
cost-effective. However, the optimal magnitude of the incen-
tives, as well as its long-term durability, remains unclear and 
therefore further research is recommended.
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